Last reviewed · How we verify
NRD135S.E1
At a glance
| Generic name | NRD135S.E1 |
|---|---|
| Also known as | E1 |
| Sponsor | Novaremed Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA (PHASE2)
- Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NRD135S.E1 CI brief — competitive landscape report
- NRD135S.E1 updates RSS · CI watch RSS
- Novaremed Ltd. portfolio CI